Progressive supranuclear palsy

Seminars in Neurology

Volumn 34, Issue 2, 2014, Pages 151-159

  Golbe, Lawrence I ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

brainstem; frontal dementia; parkinsonism; progressive supranuclear palsy; tau

Indexed keywords

AMANTADINE; AMITRIPTYLINE; BOTULINUM TOXIN; LEVODOPA; TAU PROTEIN; UBIDECARENONE;

ARTICLE; BEHAVIOR CHANGE; BODY POSTURE; BRADYKINESIA; BRAIN DISEASE; BRAIN STEM; CEREBROSPINAL FLUID; COGNITIVE DEFECT; COMORBIDITY; DISEASE COURSE; DRUG EFFICACY; DYSARTHRIA; DYSPHAGIA; EYE MOVEMENT; GAZE PARALYSIS; GENETIC RISK; HISTORY OF MEDICINE; HUMAN; MORBIDITY; MUSCLE RIGIDITY; NECK MUSCLE; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN AGGREGATION; RATING SCALE; RISK FACTOR; SLEEP AROUSAL DISORDER; SURVIVAL; URINE INCONTINENCE; NEUROLOGIC EXAMINATION; SUPRANUCLEAR PALSY, PROGRESSIVE;

AGE OF ONSET; HUMANS; NEUROLOGIC EXAMINATION; PREVALENCE; RISK FACTORS; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 84903269516     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0034-1381736     Document Type: Article

References (102)

1. Steele J. C., Richardson J. C., Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum, with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol: 1964; 10 333 359
2. Pollock N. J., Mirra S. S., Binder L. I., Hansen L. A., Wood J. G. Filamentous aggregates in Pick's disease, progressive supranuclear palsy, and Alzheimer's disease share antigenic determinants with microtubule-associated protein, tau. Lancet: 1986; 2 8517 1211
3. Baker M., Litvan I., Houlden H., et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet: 1999; 8 4 711 715
4. Albers D. S., Augood S. J., Park L. C., et al. Frontal lobe dysfunction in progressive supranuclear palsy: evidence for oxidative stress and mitochondrial impairment. J Neurochem: 2000; 74 2 878 881
5. Williams D. R., de Silva R., Paviour D. C., et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain: 2005; 128 Pt 6 1247 1258
6. Lewis J., McGowan E., Rockwood J., et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet: 2000; 25 4 402 405
7. Litvan I., Agid Y., Calne D., et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology: 1996; 47 1 1 9
8. Golbe L. I., Ohman-Strickland P. A. A clinical rating scale for progressive supranuclear palsy. Brain: 2007; 130 Pt 6 1552 1565
9. Baron J. C., Maziere B., Loc'h C., Sgouropoulos P., Bonnet A. M., Agid Y. Progressive supranuclear palsy: loss of striatal dopamine receptors demonstrated in vivo by positron tomography. Lancet: 1985; 1 8438 1163 1164
10. Nath U., Ben-Shlomo Y., Thomson R. G., et al. The prevalence of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK. Brain: 2001; 124 Pt 7 1438 1449
11. Schrag A., Ben-Shlomo Y., Quinn N. P. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet: 1999; 354 9192 1771 1775
12. Bower J. H., Maraganore D. M., McDonnell S. K., Rocca W. A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology: 1997; 49 5 1284 1288
13. Kawashima M., Miyake M., Kusumi M., Adachi Y., Nakashima K. Prevalence of progressive supranuclear palsy in Yonago, Japan. Mov Disord: 2004; 19 10 1239 1240
14. Davis P. H., Golbe L. I., Duvoisin R. C., Schoenberg B. S. Risk factors for progressive supranuclear palsy. Neurology: 1988; 38 10 1546 1552
15. Golbe L. I., Rubin R. S., Cody R. P., et al. Follow-up study of risk factors in progressive supranuclear palsy. Neurology: 1996; 47 1 148 154
16. Vidal J. S., Vidailhet M., Derkinderen P., de Gaillarbois T. D., Tzourio C., Alpérovitch A. Risk factors for progressive supranuclear palsy: a case-control study in France. J Neurol Neurosurg Psychiatry: 2009; 80 11 1271 1274
17. Odetti P., Garibaldi S., Norese R., et al. Lipoperoxidation is selectively involved in progressive supranuclear palsy. J Neuropathol Exp Neurol: 2000; 59 5 393 397
18. Golbe L. I., Davis P. H., Schoenberg B. S., Duvoisin R. C. Prevalence and natural history of progressive supranuclear palsy. Neurology: 1988; 38 7 1031 1034
19. Ghika J., Bogousslavsky J. Presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy. Arch Neurol: 1997; 54 9 1104 1108
20. Höglinger G. U., Melhem N. M., Dickson D. W., et al. Common variants affect risk for the tauopathy progressive supranuclear palsy. Nat Genet: 2011; 43 699 705
21. Ruberg M., Javoy-Agid F., Hirsch E., et al. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Ann Neurol: 1985; 18 5 523 529
22. Hauw J-J, Verny M., Delaère P., Cervera P., He Y., Duyckaerts C. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer's disease and aging. Neurosci Lett: 1990; 119 2 182 186
23. Levy R., Ruberg M., Herrero M. T., et al. Alterations of GABAergic neurons in the basal ganglia of patients with progressive supranuclear palsy: an in situ hybridization study of GAD67 messenger RNA. Neurology: 1995; 45 1 127 134
24. Pascual J., Berciano J., González A. M., Grijalba B., Figols J., Pazos A. Autoradiographic demonstration of loss of alpha 2-adrenoceptors in progressive supranuclear palsy: preliminary report. J Neurol Sci: 1993; 114 2 165 169
25. Benarroch E. E. Pedunculopontine nucleus: functional organization and clinical implications. Neurology: 2013; 80 12 1148 1155
26. Padovani A., Borroni B., Brambati S. M., et al. Diffusion tensor imaging and voxel based morphometry study in early progressive supranuclear palsy. J Neurol Neurosurg Psychiatry: 2006; 77 4 457 463
27. Sawa N., Kataoka H., Kiriyama T., et al. Cerebellar dentate nucleus in progressive supranuclear palsy. Clin Neurol Neurosurg: 2014; 118 32 36
28. Zwergal A., la Fougère C., Lorenzl S., et al. Postural imbalance and falls in PSP correlate with functional pathology of the thalamus. Neurology: 2011; 77 2 101 109
29. Liscic R. M., Srulijes K., Gröger A., Maetzler W., Berg D. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools. Acta Neurol Scand: 2013; 127 5 362 370
30. Tripathi M., Dhawan V., Peng S., et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology: 2013; 55 4 483 492
31. Ilgin N., Zubieta J., Reich S. G., Dannals R. F., Ravert H. T., Frost J. J. PET imaging of the dopamine transporter in progressive supranuclear palsy and Parkinson's disease. Neurology: 1999; 52 6 1221 1226
32. Blin J., Baron J. C., Dubois B., et al. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol: 1990; 47 7 747 752
33. Rollin-Sillaire A., Bombois S., Deramecourt V., et al. Contribution of single photon emission computed tomography to the differential diagnosis of dementia in a memory clinic. J Alzheimers Dis: 2012; 30 4 833 845
34. Van Laere K., Casteels C., De Ceuninck L., et al. Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. J Nucl Med: 2006; 47 3 384 392
35. Guevara C. A., Blain C. R., Stahl D., Lythgoe D. J., Leigh P. N., Barker G. J. Quantitative magnetic resonance spectroscopic imaging in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy. Eur J Neurol: 2010; 17 9 1193 1202
36. Albrecht P., Müller A. K., Südmeyer M., et al. Optical coherence tomography in parkinsonian syndromes. PLoS ONE: 2012; 7 4 e34891
37. Serrao M., Di Fabio R., Bartolo M., et al. The contribution of trigemino-cervical reflexes in distinguishing progressive supranuclear palsy from multiple system atrophy. Clin Neurophysiol: 2011; 122 9 1812 1815
38. Hall S., Öhrfelt A., Constantinescu R., et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch Neurol: 2012; 69 11 1445 1452
39. Winikates J., Jankovic J. Vascular progressive supranuclear palsy. J Neural Transm Suppl: 1994; 42 189 201
40. Soliveri P., Piacentini S., Girotti F. Limb apraxia in corticobasal degeneration and progressive supranuclear palsy. Neurology: 2005; 64 3 448 453
41. Johnson R. Jr, Litvan I., Grafman J. Progressive supranuclear palsy: altered sensory processing leads to degraded cognition. Neurology: 1991; 41 8 1257 1262
42. Dubois B., Pillon B., Legault F., Agid Y., Lhermitte F. Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease. Arch Neurol: 1988; 45 11 1194 1199
43. Litvan I., Mega M. S., Cummings J. L., Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology: 1996; 47 5 1184 1189
44. Pillon B., Gouider-Khouja N., Deweer B., et al. Neuropsychological pattern of striatonigral degeneration: comparison with Parkinson's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry: 1995; 58 2 174 179
45. Grafman J., Litvan I., Gomez C., Chase T. N. Frontal lobe function in progressive supranuclear palsy. Arch Neurol: 1990; 47 5 553 558
46. Podoll K., Schwarz M., Noth J. Language functions in progressive supranuclear palsy. Brain: 1991; 114 Pt 3 1457 1472
47. Cambier J., Masson M., Viader F., Limodin J., Strube A. [Frontal syndrome of progressive supranuclear palsy]. Rev Neurol (Paris): 1985; 141 8-9 528 536
48. Robbins T. W., James M., Owen A. M., et al. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry: 1994; 57 1 79 88
49. Leiguarda R. C., Pramstaller P. P., Merello M., Starkstein S., Lees A. J., Marsden C. D. Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism. Brain: 1997; 120 Pt 1 75 90
50. Barclay C. L., Bergeron C., Lang A. E. Arm levitation in progressive supranuclear palsy. Neurology: 1999; 52 4 879 882
51. Gerstenecker A., Duff K., Mast B., Litvan I.; ENGENE-PSP Study Group. Behavioral abnormalities in progressive supranuclear palsy. Psychiatry Res: 2013; 210 3 1205 1210
52. Rafal R. D., Posner M. I., Friedman J. H., Inhoff A. W., Bernstein E. Orienting of visual attention in progressive supranuclear palsy. Brain: 1988; 111 Pt 2 267 280
53. Birdi S., Rajput A. H., Fenton M., et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord: 2002; 17 6 1255 1264
54. Dubas F., Gray F., Escourolle R. [Steele-Richardson-Olszewski disease without ophthalmoplegia. 6 clinico-anatomic cases]. Rev Neurol (Paris): 1983; 139 6-7 407 416
55. Chu F. C., Reingold D. B., Cogan D. G., Williams A. C. The eye movement disorders of progressive supranuclear palsy. Ophthalmology: 1979; 86 3 422 428
56. Marx S., Respondek G., Stamelou M., et al. Validation of mobile eye-tracking as novel and efficient means for differentiating progressive supranuclear palsy from Parkinson's disease. Front Behav Neurosci: 2012; 6 88
57. Rascol O., Sabatini U., Simonetta-Moreau M., Montastruc J. L., Rascol A., Clanet M. Square wave jerks in parkinsonian syndromes. J Neurol Neurosurg Psychiatry: 1991; 54 7 599 602
58. Pierrot-Deseilligny C., Rivaud S., Pillon B., Fournier E., Agid Y. Lateral visually-guided saccades in progressive supranuclear palsy. Brain: 1989; 112 Pt 2 471 487
59. Golbe L. I., Davis P. H., Lepore F. E. Eyelid movement abnormalities in progressive supranuclear palsy. Mov Disord: 1989; 4 4 297 302
60. Maher E. R., Lees A. J. The clinical features and natural history of the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology: 1986; 36 7 1005 1008
61. Nath U., Ben-Shlomo Y., Thomson R. G., Lees A. J., Burn D. J. Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study. Neurology: 2003; 60 6 910 916
62. Matsuo H., Takashima H., Kishikawa M., et al. Pure akinesia: an atypical manifestation of progressive supranuclear palsy. J Neurol Neurosurg Psychiatry: 1991; 54 5 397 400
63. Williams D. R., Holton J. L., Strand K., Revesz T., Lees A. J. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord: 2007; 22 15 2235 2241
64. Tanigawa A., Komiyama A., Hasegawa O. Truncal muscle tonus in progressive supranuclear palsy. J Neurol Neurosurg Psychiatry: 1998; 64 2 190 196
65. Ling H., Massey L. A., Lees A. J., Brown P., Day B. L. Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain: 2012; 135 Pt 4 1141 1153
66. Sixel-Döring F., Schweitzer M., Mollenhauer B., Trenkwalder C. Polysomnographic findings, video-based sleep analysis and sleep perception in progressive supranuclear palsy. Sleep Med: 2009; 10 4 407 415
67. Aldrich M. S., Foster N. L., White R. F., Bluemlein L., Prokopowicz G. Sleep abnormalities in progressive supranuclear palsy. Ann Neurol: 1989; 25 6 577 581
68. Leygonie F., Thomas J., Degos J. D., Bouchareine A., Barbizet J. [Sleep disorders in Steele-Richardson disease. Polygraphic study of 3 cases]. Rev Neurol (Paris): 1976; 132 2 125 136
69. Agid Y., Javoy-Agid F., Ruberg M., et al. Progressive supranuclear palsy: anatomoclinical and biochemical considerations. Adv Neurol: 1987; 45 191 206
70. Vidailhet M., Rothwell J. C., Thompson P. D., Lees A. J., Marsden C. D. The auditory startle response in the Steele-Richardson-Olszewski syndrome and Parkinson's disease. Brain: 1992; 115 Pt 4 1181 1192
71. Skodda S., Visser W., Schlegel U. Acoustical analysis of speech in progressive supranuclear palsy. J Voice: 2011; 25 6 725 731
72. Kluin K. J., Foster N. L., Berent S., Gilman S. Perceptual analysis of speech disorders in progressive supranuclear palsy. Neurology: 1993; 43 3 Pt 1 563 566
73. Müller J., Wenning G. K., Verny M., et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol: 2001; 58 2 259 264
74. Sonies B. C. Swallowing and speech disturbances. In: Litvan I., Agid Y., eds. Progressive Supranuclear Palsy: Clinical and Research Approaches. New York Oxford University Press: 1992; 240 254
75. Johnston B. T., Castell J. A., Stumacher S., et al. Comparison of swallowing function in Parkinson's disease and progressive supranuclear palsy. Mov Disord: 1997; 12 3 322 327
76. Leopold N. A., Kagel M. C. Dysphagia in progressive supranuclear palsy: radiologic features. Dysphagia: 1997; 12 3 140 143
77. Warnecke T., Oelenberg S., Teismann I., et al. Endoscopic characteristics and levodopa responsiveness of swallowing function in progressive supranuclear palsy. Mov Disord: 2010; 25 9 1239 1245
78. Testa D., Monza D., Ferrarini M., Soliveri P., Girotti F., Filippini G. Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurol Sci: 2001; 22 3 247 251
79. Sakakibara R., Hattori T., Tojo M., Yamanishi T., Yasuda K., Hirayama K. Micturitional disturbance in progressive supranuclear palsy. J Auton Nerv Syst: 1993; 45 2 101 106
80. Kimber J., Mathias C. J., Lees A. J., et al. Physiological, pharmacological and neurohormonal assessment of autonomic function in progressive supranuclear palsy. Brain: 2000; 123 Pt 7 1422 1430
81. Litvan I., Agid Y., Jankovic J., et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology: 1996; 46 4 922 930
82. Hauw J-J, Daniel S. E., Dickson D., et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology: 1994; 44 11 2015 2019
83. O'Sullivan S. S., Massey L. A., Williams D. R., et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain: 2008; 131 Pt 5 1362 1372
84. dell'Aquila C., Zoccolella S., Cardinali V., et al. Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients. Parkinsonism Relat Disord: 2013; 19 11 980 985
85. Burn D. J. Clinical assessment of progressive supranuclear palsy over time: new rating scale validated. Nat Clin Pract Neurol: 2007; 3 11 600 601
86. Hall D. A., João Forjaz M., Golbe L. I., et al. Scales to assess clinical features of progressive supranuclear palsy. MDS Task Force Report. Mov Disord, In press
87. Nieforth K. A., Golbe L. I. Retrospective study of drug response in 87 patients with progressive supranuclear palsy. Clin Neuropharmacol: 1993; 16 4 338 346
88. D'Costa D. F., Abbott R. J., Pye I. F., Millac P. A. The apomorphine test in parkinsonian syndromes. J Neurol Neurosurg Psychiatry: 1991; 54 10 870 872
89. Weiner W. J., Minagar A., Shulman L. M. Pramipexole in progressive supranuclear palsy. Neurology: 1999; 52 4 873 874
90. Stamelou M., Reuss A., Pilatus U., et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord: 2008; 23 7 942 949
91. Newman G. C. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology: 1985; 35 8 1189 1193
92. Bensimon G., Ludolph A., Agid Y., Vidailhet M., Payan C., Leigh P. N.; NNIPPS Study Group. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain: 2009; 132 Pt 1 156 171
93. Tolosa E., Litvan I., Höglinger G. U., et al. TAUROS Investigators. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord: 2014; 29 4 470 478
94. Piccione F., Mancini E., Tonin P., Bizzarini M. Botulinum toxin treatment of apraxia of eyelid opening in progressive supranuclear palsy: report of two cases. Arch Phys Med Rehabil: 1997; 78 5 525 529
95. Krack P., Marion M. H. Apraxia of lid opening, a focal eyelid dystonia: clinical study of 32 patients. Mov Disord: 1994; 9 6 610 615
96. Litvan I., Phipps M., Pharr V. L., Hallett M., Grafman J., Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology: 2001; 57 3 467 473
97. Fabbrini G., Barbanti P., Bonifati V., et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand: 2001; 103 2 123 125
98. Liepelt I., Gaenslen A., Godau J., et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement: 2010; 6 1 70 74
99. Sosner J., Wall G. C., Sznajder J. Progressive supranuclear palsy: clinical presentation and rehabilitation of two patients. Arch Phys Med Rehabil: 1993; 74 5 537 539
100. Suteerawattananon M., MacNeill B., Protas E. J. Supported treadmill training for gait and balance in a patient with progressive supranuclear palsy. Phys Ther: 2002; 82 5 485 495
101. Steffen T. M., Boeve B. F., Petersen C. M., Dvorak L., Kantarci K. Long-term exercise training for an individual with mixed corticobasal degeneration and progressive supranuclear palsy features: 10-year case report follow-up. Phys Ther: 2014; 94 2 289 296
102. Zampieri C., Di Fabio R. P. Improvement of gaze control after balance and eye movement training in patients with progressive supranuclear palsy: a quasi-randomized controlled trial. Arch Phys Med Rehabil: 2009; 90 2 263 270